BlackRock Health Sciences Trust II (BMEZ)
NYSE 
BMEZ: Option Income CEF With Steep NAV Discount Ready For Biotech Recovery
BlackRock raised dividends for BMEZ, offering a monthly distribution of $0.1789 with a 14.24% yield, showing confidence in the fund's future. BMEZ shares have been bought back multiple times in 2024, indicating strong tailwinds for the fund's stock price. BMEZ is a buy with high-yield and unique sector diversification in the biotechnology industry, expected to rebound significantly in 2024.
Private Advisor Group LLC Has $524,000 Stock Holdings in BlackRock Health Sciences Term Trust (NYSE:BMEZ)
Private Advisor Group LLC raised its stake in BlackRock Health Sciences Term Trust (NYSE:BMEZ – Free Report) by 24.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,791 shares of the company’s stock after purchasing an additional 6,935 shares during the period. Private Advisor Group LLC’s holdings in BlackRock Health Sciences Term Trust were worth $524,000 at the end of the most recent quarter. Other large investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. raised its holdings in BlackRock Health Sciences Term Trust by 4.8% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 17,363 shares of the company’s stock valued at $250,000 after acquiring an additional 796 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of BlackRock Health Sciences Term Trust by 24.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 4,792 shares of the company’s stock worth $70,000 after buying an additional 930 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in shares of BlackRock Health Sciences Term Trust by 4.0% in the third quarter. Janney Montgomery Scott LLC now owns 30,936 shares of the company’s stock valued at $446,000 after acquiring an additional 1,199 shares in the last quarter. LPL Financial LLC raised its stake in BlackRock Health Sciences Term Trust by 0.5% in the 3rd quarter. LPL Financial LLC now owns 274,665 shares of the company’s stock worth $3,958,000 after purchasing an additional 1,231 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in BlackRock Health Sciences Term Trust by 22.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 25,955 shares of the company’s stock valued at $374,000 after purchasing an additional 4,745 shares during the period. Insider Activity In other news, major shareholder Saba Capital Management, L.P. acquired 193,297 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of 15.92 per share, with a total value of 3,077,288.24. Following the completion of the purchase, the insider now directly owns 19,578,308 shares of the company’s stock, valued at approximately 311,686,663.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders bought 701,207 shares of company stock worth $11,338,909. BlackRock Health Sciences Term Trust Trading Down 0.1 % NYSE BMEZ opened at 15.10 on Monday. The company has a 50 day moving average of 15.46 and a 200-day moving average of 15.10. BlackRock Health Sciences Term Trust has a 1-year low of 12.93 and a 1-year high of 16.59. BlackRock Health Sciences Term Trust Announces Dividend The company also recently announced a monthly dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 15th will be issued a $0.09 dividend. This represents a $1.08 annualized dividend and a yield of 7.15%. The ex-dividend date is Tuesday, May 14th. BlackRock Health Sciences Term Trust Company Profile (Free Report) BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.
